+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Histology and Cytology Market Size, Share & Trends Analysis Report by End Use, by Product (Instruments & Analysis Software System, Consumables & Reagents), by Type of Examination, and Segment Forecasts, 2020 - 2027

  • ID: 4761215
  • Report
  • February 2020
  • Region: Global
  • 160 pages
  • Grand View Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott
  • Danaher
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Koninklijke Philips N.V.
  • Merck KGaA
  • MORE
The global histology and cytology market size is expected to reach USD 34.5 billion by 2027 growing at a CAGR of 13.6%. Significance for cell-based models in phenotypic assays has increased over the years, mainly targeted towards discovering new disease causative factors while performing an in-depth analysis of disease mechanism and detecting biomarkers with clinical significance. This has fueled the demand for cytological profiling as well as histopathology techniques contributing to the overall growth.

Histology involves microscopic examination of whole tissue samples whereas, cytology includes individualized cellular analysis targeted towards particular disease condition. Cytology is frequently utilized to perform a primary screening of the diseases, based on which the pathologists perform further diagnosis of the patient.

Emerging immunohistochemistry techniques along with the advancements across histology products such as enclosed tissue processors, cryostats, disposable knives, and plastic cassettes is expected to propel market growth. Splurging demand for in-vitro diagnostics is expected to propel the demand for histology among the laboratory professionals.

Further key findings from the study suggest:
  • Cytology accounted for the highest revenue generated in 2019 and is anticipated to maintain this trend throughout the forecast period
  • Cervical cancer is the major contributor to the revenue generated in the cytology segment and is anticipated to witness a CAGR of 11.9% from 2020 to 2027
  • Consumable and reagents have dominated the global histology & cytology market attributed to their large-scale adoption across various protocols right from tissue acquisition to processing or treatment
  • The life sciences end-use segment is set grow at a fastest pace registering a CAGR of 13.9% attributed to increasing employment of digital histology and cytology instruments across oncology and toxicology studies
  • North America accounted for the largest revenue share in 2019 owing to sufficient presence of skilled professionals required to maintain the efficacy of these tests
  • Asia Pacific is expected to offer lucrative opportunities for market expansion, attributed to rising focus on the development of advanced diagnostic techniques
  • International players looking to invest in developing economies of this region have significantly contributed to the projected revenue in this region
  • Some of the key market participants are Abbott, Hologic, Inc., F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company (BD)
  • In the recent years, the market has witnessed pivotal collaborations amongst the participants for the launch of unique solutions
  • For instance, in December 2019, F. Hoffmann-La Roche Ltd collaborated with Fortelinea Software Systems targeted towards co-marketing of software solutions in U.S. This was aimed at enhancing workflow across histology research laboratories in the country.

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott
  • Danaher
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Koninklijke Philips N.V.
  • Merck KGaA
  • MORE
Chapter 1 Research Methodology & Scope
1.1 Information procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Histology & Cytology Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Rising incidence of cancer
3.1.1.2 Technological developments
3.1.1.3 Increase in awareness programs for cervical cancer screening
3.1.2 Market restraint analysis
3.1.2.1 Low sensitivity of cytology tests
3.1.2.2 Conditions required for specimens and problem of mislabeled specimens
3.2 Penetration & Growth Prospect Mapping for Products, 2019
3.3 Histology and cytology Market-SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter’s
3.5 Regulatory Framework
3.5.1 U.K.
3.5.2 U.S.
3.6 Reimbursement Scenario
3.7 Research Institutes: Histology and Cytology Market

Chapter 4 Histology and Cytology Market: Type of Examination Estimates & Trend Analysis
4.1 Histology and Cytology Market: Type of Examination Movement Analysis
4.2 Histology
4.2.1 Histology market, 2016 - 2027 (USD Million)
4.3 Cytology
4.3.1 Cytology market, 2016 - 2027 (USD Million)
4.3.2 Cervical cancer
4.3.2.1 Cervical cancer cytology market, 2016 - 2027 (USD Million)
4.3.3 Breast cancer
4.3.3.1 Breast cancer cytology market, 2016 - 2027 (USD Million)
4.3.4 Other cancers
4.3.4.1 Pancreatic cancer
4.3.4.2 Bile duct
4.3.4.3 Bladder cancer
4.3.4.4 Other cancers cytology market, 2016 - 2027 (USD Million)

Chapter 5 Histology and Cytology Market: Product Estimates & Trend Analysis
5.1 Histology and Cytology Market: Product Movement Analysis
5.2 Instruments and Analysis Software System
5.2.1 Histology and cytology instruments & analysis software system market, 2016 - 2027 (USD Million)
5.3 Consumable and Reagents
5.3.1 Histology and cytology consumable & reagents market, 2016 - 2027 (USD Million)

Chapter 6 Histology and Cytology Market: End-use Estimates & Trend Analysis
6.1 Histology and Cytology Market: End-use Movement Analysis
6.2 Life Sciences
6.2.1 Life science histology and cytology market, 2016 - 2027 (USD Million)
6.3 Clinical Diagnostics
6.3.1 Histology and cytology clinical diagnostics market, 2016 - 2027 (USD Million)

Chapter 7 Histology and cytology: Regional Estimates & Trend Analysis, by Type of Examination, Product, & End-use
7.1 Histology and cytology Market share by region, 2018 & 2026
7.2 Market Players, by Region
7.3 SWOT Analysis, by Region
7.4 North America
7.4.1 North America histology and cytology market, 2016 - 2027 (USD Million)
7.4.2 U.S.
7.4.2.1 U.S. histology and cytology market, 2016 - 2027 (USD Million)
7.4.3 Canada
7.4.3.1 Canada histology and cytology market, 2016 - 2027 (USD Million)
7.5 Europe
7.5.1 Europe histology and cytology market, 2016 - 2027 (USD Million)
7.5.2 Germany
7.5.2.1 Germany histology and cytology market, 2016 - 2027 (USD Million)
7.5.3 U.K.
7.5.3.1 U.K. histology and cytology market, 2016 - 2027 (USD Million)
7.5.4 France
7.5.4.1 France histology and cytology market, 2016 - 2027 (USD Million)
7.5.5 Italy
7.5.5.1 Italy histology and cytology market, 2016 - 2027 (USD Million)
7.5.6 Spain
7.5.6.1 Spain histology and cytology market, 2016 - 2027 (USD Million)
7.6 Asia Pacific
7.6.1 Asia Pacific histology and cytology market, 2016 - 2027 (USD Million)
7.6.2 China
7.6.2.1 China histology and cytology market, 2016 - 2027 (USD Million)
7.6.3 Japan
7.6.3.1 Japan histology and cytology market, 2016 - 2027 (USD Million)
7.7 Latin America
7.7.1 Latin America histology and cytology market, 2016 - 2027 (USD Million)
7.7.2 Brazil
7.7.2.1 Brazil histology and cytology market, 2016 - 2027 (USD Million)
7.7.3 Mexico
7.7.3.1 Mexico histology and cytology market, 2016 - 2027 (USD Million)
7.8 Middle East and Africa (MEA)
7.8.1 MEA histology and cytology market, 2016 - 2027 (USD Million)
7.8.2 South Africa
7.8.2.1 South Africa histology and cytology market, 2016 - 2027 (USD Million)

Chapter 8 Competitive Landscape
8.1 Strategy Framework
8.2 Company Profiles
8.2.1 Hologic, Inc.
8.2.1.1 Company overview
8.2.1.2 Financial performance
8.2.1.3 Product benchmarking
8.2.1.4 Strategic initiatives
8.2.2 F. Hoffmann-La Roche Ltd.
8.2.2.1 Company overview
8.2.2.2 Financial performance
8.2.2.3 Product benchmarking
8.2.2.4 Strategic initiatives
8.2.3 Abbott
8.2.3.1 Company overview
8.2.3.2 Financial performance
8.2.3.3 Product benchmarking
8.2.4 Becton, Dickinson & Company
8.2.4.1 Company overview
8.2.4.2 Financial performance
8.2.4.3 Product benchmarking
8.2.4.4 Strategic initiatives
8.2.5 Danaher
8.2.5.1 Company overview
8.2.5.2 Financial performance
8.2.5.3 Product benchmarking
8.2.5.4 Strategic initiatives
8.2.6 Merck KGaA
8.2.6.1 Company overview
8.2.6.2 Financial performance
8.2.6.3 Product benchmarking
8.2.6.4 Strategic initiatives
8.2.7 Thermo Fisher Scientific, Inc.
8.2.7.1 Company overview
8.2.7.2 Financial performance
8.2.7.3 Product benchmarking
8.2.7.4 Strategic initiatives
8.2.8 Sysmex Corporation
8.2.8.1 Company overview
8.2.8.2 Financial performance
8.2.8.3 Product benchmarking
8.2.8.4 Strategic initiatives
8.2.9 Trivitron Healthcare
8.2.9.1 Company overview
8.2.9.2 Financial performance
8.2.9.3 Product benchmarking
8.2.9.4 Strategic initiatives
8.2.10 Koninklijke Philips N.V.
8.2.10.1 Company overview
8.2.10.2 Financial performance
8.2.10.3 Product benchmarking
8.2.10.4 Strategic initiatives


*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Hologic, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Abbott
  • Becton, Dickinson & Company
  • Danaher
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Sysmex Corporation
  • Trivitron Healthcare
  • Koninklijke Philips N.V.
Note: Product cover images may vary from those shown
Adroll
adroll